|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
SI3988660T1
(sl)
|
2009-05-02 |
2025-09-30 |
Genzyme Corporation |
Genska terapija za nevrodegenerativne motnje
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
DK3693025T3
(da)
|
2011-04-22 |
2022-01-10 |
Univ California |
Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
|
|
JP2016523835A
(ja)
|
2013-05-15 |
2016-08-12 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
|
|
US11136557B2
(en)
|
2013-05-31 |
2021-10-05 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
EP3564379A1
(en)
|
2013-09-13 |
2019-11-06 |
California Institute of Technology |
Selective recovery
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
ES2822551T3
(es)
|
2014-03-17 |
2021-05-04 |
Adverum Biotechnologies Inc |
Composiciones y métodos para la expresión génica mejorada en células de los conos
|
|
JP6756700B2
(ja)
|
2014-03-18 |
2020-09-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症を処置するためのｒＡＡＶベースの組成物および方法
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
LT3137497T
(lt)
|
2014-05-02 |
2021-07-26 |
Genzyme Corporation |
Aav vektoriai, skirti tinklainės ir cns genų terapijai
|
|
SG11201609314XA
(en)
*
|
2014-05-14 |
2016-12-29 |
Esteve Labor Dr |
Adenoassociated virus vectors for the treatment of lysosomal storage disorders
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2016054557A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Novel high efficiency library-identified aav vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
EA201791803A1
(ru)
*
|
2015-02-10 |
2017-11-30 |
Джензим Корпорейшн |
Улучшенная доставка вирусных частиц в полосатое тело и кору больших полушарий
|
|
CA3255657A1
(en)
|
2015-02-10 |
2025-12-01 |
Genzyme Corporation |
VARIANT RNAi
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
FI3265178T3
(fi)
|
2015-03-02 |
2026-08-03 |
Adverum Biotechnologies Inc |
Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
|
|
CA2979229A1
(en)
*
|
2015-03-11 |
2016-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Rp2 vectors for treating x-linked retinitis pigmentosa
|
|
JP6836999B2
(ja)
|
2015-03-24 |
2021-03-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ |
アデノ随伴ウイルス変異体及びその使用方法
|
|
SG11201708257UA
(en)
|
2015-04-06 |
2017-11-29 |
Subdomain Llc |
De novo binding domain containing polypeptides and uses thereof
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
EP3280451B8
(en)
|
2015-04-08 |
2019-09-25 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Viral gene therapy as treatment for cholesterol storage disease or disorder
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
EP3364997B1
(en)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gene therapy in the treatment of canavan disease
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
US20180230489A1
(en)
|
2015-10-28 |
2018-08-16 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
AU2016366549B2
(en)
|
2015-12-11 |
2022-11-10 |
California Institute Of Technology |
Targeting peptides for directing adeno-associated viruses (AAVs)
|
|
SG10201912935WA
(en)
*
|
2015-12-15 |
2020-02-27 |
Genzyme Corp |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US20190071681A1
(en)
*
|
2016-02-26 |
2019-03-07 |
University Of Florida Research Foundation, Incorporated |
Aav heparin mutants that display significantly improved eye and brain transduction
|
|
EP3440210A4
(en)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
COMPOSITIONS AND METHOD FOR SELECTIVELY INHIBITING THE EXPRESSION OF GRAINYHEAD LIKE PROTEIN
|
|
CN107287238B
(zh)
*
|
2016-04-11 |
2020-10-16 |
厦门继景生物技术有限责任公司 |
一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
GB201608046D0
(en)
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
IL297576B2
(en)
|
2016-05-18 |
2024-02-01 |
Voyager Therapeutics Inc |
Compositions and methods of treating huntington's disease
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
US11197936B2
(en)
*
|
2016-07-08 |
2021-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
|
US11458211B2
(en)
|
2016-07-12 |
2022-10-04 |
The University Of Manchester |
Gene therapy
|
|
CN109640949B
(zh)
|
2016-07-29 |
2022-11-25 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体和其使用方法
|
|
CA3033125A1
(en)
*
|
2016-08-16 |
2018-02-22 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
CA3034089A1
(en)
*
|
2016-08-18 |
2018-02-22 |
The Regents Of The University Of California |
Crispr-cas genome engineering via a modular aav delivery system
|
|
ES2982489T3
(es)
|
2016-08-19 |
2024-10-16 |
Univ Florida |
Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios
|
|
EP3500279A4
(en)
*
|
2016-08-19 |
2020-04-22 |
Calimmune, Inc. |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANINE CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS.
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3519431A1
(en)
|
2016-09-28 |
2019-08-07 |
Cohbar Inc. |
Therapeutic mots-c related peptides
|
|
US11078238B2
(en)
|
2016-09-29 |
2021-08-03 |
University Of Florida Research Foundation, Incorporated |
AAVrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
AU2017345470B2
(en)
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
US11958886B2
(en)
|
2016-12-07 |
2024-04-16 |
University Of Florida Research Foundation, Incorporated |
IL-1RA cDNAs
|
|
WO2018145009A1
(en)
*
|
2017-02-06 |
2018-08-09 |
University Of Tennessee Research Foundation |
Dna-zyme based methods & compositions for treating huntington's disease
|
|
US11117930B2
(en)
|
2017-02-23 |
2021-09-14 |
Adrx, Inc. |
Peptide inhibitors of transcription factor aggregation
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
CA3059891A1
(en)
|
2017-04-14 |
2018-10-18 |
National Taiwan University |
Gene therapy for aadc deficiency
|
|
WO2018200419A1
(en)
*
|
2017-04-23 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Viral vectors comprising engineered aav capsids and compositions containing the same
|
|
MX2019013172A
(es)
*
|
2017-05-05 |
2020-09-07 |
Voyager Therapeutics Inc |
Composiciones y metodos para tratar la enfermedad de huntington.
|
|
AU2018264996A1
(en)
|
2017-05-09 |
2019-12-05 |
University Of Massachusetts |
Methods of treating Amyotrophic Lateral Sclerosis (ALS)
|
|
WO2018209154A1
(en)
*
|
2017-05-10 |
2018-11-15 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for modifying assembly-activating protein (app)-dependence of viruses
|
|
WO2018226992A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
KR20250023600A
(ko)
*
|
2017-06-30 |
2025-02-18 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
|
|
CA3071769A1
(en)
|
2017-07-31 |
2019-02-07 |
Reflection Biotechnologies Limited |
Cellular models of and therapies for ocular diseases
|
|
US11512327B2
(en)
|
2017-08-03 |
2022-11-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of AAV
|
|
MX2020001997A
(es)
|
2017-08-28 |
2020-07-20 |
Univ California |
Variantes de capside de virus adenoasociado y metodos de uso de estas.
|
|
MX2020003095A
(es)
|
2017-09-22 |
2020-10-15 |
Genzyme Corp |
Arni variante.
|
|
US20200377887A1
(en)
*
|
2017-09-22 |
2020-12-03 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
|
CN118006607A
(zh)
|
2017-09-22 |
2024-05-10 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
AU2018350700B2
(en)
*
|
2017-10-16 |
2025-04-24 |
VeonGen Therapeutics GmbH |
AAV vectors
|
|
KR102763312B1
(ko)
|
2017-10-20 |
2025-02-07 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
치료적으로 유효한 양의 재조합 aav9- 유도 벡터의 망막하 전달을 포함하는 대상체의 원추 광수용체 내 관심의 폴리뉴클레오티드를 발현하는 방법
|
|
US11464803B2
(en)
|
2017-11-14 |
2022-10-11 |
Arcellx, Inc. |
D-domain containing polypeptides and uses thereof
|
|
AU2018368431B2
(en)
|
2017-11-14 |
2024-03-21 |
Arcellx, Inc. |
Multifunctional immune cell therapies
|
|
SMT202400321T1
(it)
*
|
2017-11-15 |
2024-11-15 |
Univ Michigan Regents |
Vettori virali comprendenti regioni codificanti rdh12 e metodi di trattamento di distrofie retiniche
|
|
WO2019097454A1
(en)
*
|
2017-11-15 |
2019-05-23 |
Friedrich Miescher Institute For Biomedical Research |
Primate retinal pigment epithelium cell-specific promoter
|
|
EP3714055A1
(en)
|
2017-11-21 |
2020-09-30 |
CRISPR Therapeutics AG |
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
|
|
CN108085316B
(zh)
*
|
2017-12-25 |
2021-02-09 |
中国人民解放军第四军医大学 |
一种通过抑制微小核糖核酸来促进小鼠视网膜前体细胞体外扩增的方法
|
|
EP3768327A4
(en)
*
|
2018-03-23 |
2022-04-13 |
The Trustees of Columbia University in the City of New York |
GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
CA3095179A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
IL278213B2
(en)
|
2018-04-27 |
2026-04-01 |
Rocket Pharmaceuticals Ltd |
A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
|
|
WO2019222329A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112424359A
(zh)
|
2018-05-15 |
2021-02-26 |
沃雅戈治疗公司 |
用于治疗帕金森氏病的组合物和方法
|
|
WO2019221992A1
(en)
|
2018-05-15 |
2019-11-21 |
President And Fellows Of Harvard College |
Viral vectors exhibiting improved gene delivery properties
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
EP3802836A4
(en)
*
|
2018-06-01 |
2022-10-19 |
University of Florida Research Foundation, Incorporated |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT RETINITIS PIGMENTOSA
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
TW202509215A
(zh)
|
2018-08-03 |
2025-03-01 |
美商健臻公司 |
針對α-突觸核蛋白的變體RNAi
|
|
CN109022487A
(zh)
*
|
2018-08-15 |
2018-12-18 |
上海市第人民医院 |
一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
|
|
US11149256B2
(en)
|
2018-09-26 |
2021-10-19 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
US12281321B2
(en)
|
2018-09-28 |
2025-04-22 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
US20210371470A1
(en)
|
2018-10-12 |
2021-12-02 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN120349985A
(zh)
*
|
2018-10-12 |
2025-07-22 |
建新公司 |
通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
US20230061069A1
(en)
*
|
2018-11-13 |
2023-03-02 |
Jayandharan Giridhara Rao |
A process for producing a plurality of sumoylation target-site modified aav vector and product thereof
|
|
IL283452B2
(en)
*
|
2018-11-26 |
2026-04-01 |
Univ Barcelona Autonoma |
FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY
|
|
CA3121247A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
WO2020140007A1
(en)
*
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
|
KR20210112339A
(ko)
*
|
2019-01-04 |
2021-09-14 |
울트라제닉스 파마수티컬 인코포레이티드 |
윌슨병을 치료하기 위한 유전자 요법 구축물
|
|
CA3125770A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
WO2020154535A1
(en)
*
|
2019-01-23 |
2020-07-30 |
University Of Florida Research Foundation, Incorporated |
Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
|
|
SG11202107761SA
(en)
|
2019-01-28 |
2021-08-30 |
Cohbar Inc |
Therapeutic peptides
|
|
CN113795575A
(zh)
|
2019-02-04 |
2021-12-14 |
自由行疗法有限公司 |
多核苷酸
|
|
WO2020180951A1
(en)
*
|
2019-03-04 |
2020-09-10 |
Adverum Biotechnologies, Inc. |
Sequential intravitreal administration of aav gene therapy to contralateral eyes
|
|
JP7549360B2
(ja)
*
|
2019-03-04 |
2024-09-11 |
デューク ユニバーシティ |
網膜症の診断および処置のための組成物および方法
|
|
WO2020182722A1
(en)
*
|
2019-03-08 |
2020-09-17 |
Universite Paris-Saclay |
Improved therapeutic method for rare ocular diseases by gene replacement
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
JP7664848B2
(ja)
*
|
2019-04-10 |
2025-04-18 |
プリベイル セラピューティクス，インコーポレーテッド |
リソソーム障害のための遺伝子療法
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
US12491263B2
(en)
|
2019-05-13 |
2025-12-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Polymer-based implant for retinal therapy and methods of making and using the same
|
|
JP7707081B2
(ja)
*
|
2019-05-17 |
2025-07-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
網膜細胞を標的とした最適化された遺伝子治療
|
|
PE20220233A1
(es)
*
|
2019-06-10 |
2022-02-07 |
Homology Medicines Inc |
Composiciones de virus adenoasociados para la transferencia del gen de arsa y metodos de uso de las mismas
|
|
CN114269352A
(zh)
*
|
2019-06-27 |
2022-04-01 |
佛罗里达大学研究基金会 |
用透明质酸增强aav介导的眼组织转导
|
|
US11446084B2
(en)
|
2019-07-12 |
2022-09-20 |
Neuralink Corp. |
Laser drilling of pia mater
|
|
SMT202400486T1
(it)
*
|
2019-07-15 |
2025-01-14 |
Meiragtx Uk Ii Ltd |
Proteine di capside avv modificate per il trattamento della malattia artritica
|
|
CN110295151A
(zh)
*
|
2019-07-17 |
2019-10-01 |
博鑫仪器(天津)有限公司 |
一类腺依赖病毒病毒重组质粒、重组病毒及构建方法
|
|
EP4017873A4
(en)
*
|
2019-08-23 |
2023-12-20 |
Duke University |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL PAIN AND ITCH
|
|
EP4025258A4
(en)
*
|
2019-09-03 |
2023-09-06 |
University of Cincinnati |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
CA3153727A1
(en)
*
|
2019-09-10 |
2021-03-18 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Treatment methods for eye disorders
|
|
IL291944A
(en)
|
2019-10-10 |
2022-06-01 |
Solid Biosciences Inc |
Modified aav capsids and uses thereof
|
|
CN114787180A
(zh)
*
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
MX2022004353A
(es)
|
2019-10-17 |
2022-07-19 |
|
Casete de transferencia de aav.
|
|
JP7697943B2
(ja)
*
|
2019-10-23 |
2025-06-24 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
導入遺伝子発現のｄｒｇ特異的低減のための組成物
|
|
EP4055030A4
(en)
*
|
2019-11-08 |
2024-05-22 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
EP4055034A4
(en)
|
2019-11-08 |
2024-05-29 |
President And Fellows Of Harvard College |
VIRAL CAPSID POLYPEPTIDES
|
|
CN113025618B
(zh)
*
|
2019-12-24 |
2024-02-06 |
朗信启昇(苏州)生物制药有限公司 |
一种x连锁遗传性视网膜劈裂症的基因治疗方案与应用
|
|
WO2021155137A1
(en)
|
2020-01-29 |
2021-08-05 |
Genzyme Corporation |
Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
|
|
AU2021217222A1
(en)
*
|
2020-02-07 |
2022-09-29 |
The Trustees Of Columbia University In The City Of New York |
Reprogramming the metabolome to delay onset or treat neurodegeneration
|
|
CN115210248A
(zh)
*
|
2020-02-18 |
2022-10-18 |
北卡罗来纳大学查佩尔希尔分校 |
Aav衣壳-启动子相互作用和细胞选择性基因表达
|
|
EP4110913A4
(en)
*
|
2020-02-28 |
2024-07-24 |
University of Massachusetts |
OLIGONUCLEOTIDES FOR PRNP MODULATION
|
|
MX2022011177A
(es)
|
2020-03-11 |
2022-12-13 |
Massachusetts Eye & Ear Infirmary |
Terapia genica para la degeneracion de la retina asociada a nmnat1.
|
|
BR112022019304A2
(pt)
*
|
2020-03-31 |
2022-12-06 |
Univ Massachusetts |
Variantes de capsídeo de aav e usos das mesmas
|
|
CN115379863A
(zh)
*
|
2020-04-14 |
2022-11-22 |
吉尼松公司 |
用于治疗酸性神经酰胺酶缺乏症的载体
|
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
US12630842B2
(en)
|
2020-05-13 |
2026-05-19 |
Voyager Therapeutics, Inc. |
Redirection of tropism of AAV capsids
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
JP2023529503A
(ja)
*
|
2020-06-13 |
2023-07-10 |
オクロジェネクス インコーポレイテッド |
網膜症のためのａａｖ媒介性遺伝子導入
|
|
CN113952472A
(zh)
*
|
2020-07-21 |
2022-01-21 |
英斯培瑞有限公司 |
用于治疗眼部疾病的组合物和方法
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
BR112023001456A2
(pt)
|
2020-07-27 |
2023-04-11 |
Voyager Therapeutics Inc |
Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
|
|
IL300187A
(en)
|
2020-08-05 |
2023-03-01 |
Spacecraft Seven Llc |
Gene therapy CSRP3 (protein 3 rich in cysteine and glycine)
|
|
AU2021321412A1
(en)
|
2020-08-05 |
2023-04-06 |
Spacecraft Seven, Llc |
Adeno-associated viral vector for GLUT1 expression and uses thereof
|
|
WO2022032226A1
(en)
|
2020-08-07 |
2022-02-10 |
Spacecraft Seven, Llc |
Plakophilin-2 (pkp2) gene therapy using aav vector
|
|
JP2023542614A
(ja)
*
|
2020-08-19 |
2023-10-11 |
サレプタ セラピューティクス， インコーポレイテッド |
レット症候群の治療のためのアデノ随伴ウイルスベクター
|
|
AU2021335601A1
(en)
*
|
2020-09-04 |
2023-04-06 |
Ohio State Innovation Foundation |
Novel engineered capsid serotype of recombinant adeno-associated viral vector with enhanced transduction efficiency and widespread distribution in the brain
|
|
MX2023003655A
(es)
|
2020-09-29 |
2023-06-22 |
Neuexcell Therapeutics Inc |
Vector neurod1.
|
|
WO2022087238A1
(en)
*
|
2020-10-21 |
2022-04-28 |
Wisconsin Alumni Research Foundation |
Anti-apoptotic vector and method of using the same
|
|
US20220160825A1
(en)
*
|
2020-11-25 |
2022-05-26 |
The Penn State Research Foundation |
Brain repair after traumatic brain injury through neurod1-mediated astrocyte-to-neuron conversion
|
|
JP7895637B2
(ja)
*
|
2021-02-22 |
2026-07-28 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
眼病態に対するウイルスベクターベースの遺伝子療法
|
|
CN115044614B
(zh)
*
|
2021-03-09 |
2023-10-20 |
上海目镜生物医药科技有限公司 |
一种用于基因靶向与表达的aav-8型血清型的改造型载体及其构建方法及应用
|
|
US20240218396A1
(en)
*
|
2021-04-26 |
2024-07-04 |
Grace Science, Llc |
Compositions and methods for treating ngyl1 deficiency
|
|
EP4333903A4
(en)
*
|
2021-05-03 |
2025-03-19 |
North Carolina State University |
COMPOSITIONS AND METHODS RELATED TO THE TREATMENT OF OPHTHALMIC DISEASES IN HORSES
|
|
CN115997012B
(zh)
*
|
2021-09-06 |
2024-03-08 |
辉大(上海)生物科技有限公司 |
Rpe65相关眼睛疾病和障碍的治疗
|
|
US20250049955A1
(en)
|
2021-11-17 |
2025-02-13 |
Voyager Therapeutics, Inc. |
Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CA3238867A1
(en)
|
2021-11-29 |
2023-06-01 |
Shanghai Regenelead Therapies Co., Ltd. |
Aadc/gdnf polynucleotide, and use thereof in treating parkinson's disease
|
|
WO2023155918A1
(zh)
|
2022-02-21 |
2023-08-24 |
上海瑞宏迪医药有限公司 |
Vegf结合分子及其医药用途
|
|
US20250213727A1
(en)
*
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
JP2025516136A
(ja)
*
|
2022-04-19 |
2025-05-27 |
シャンハイ ヴァイタルゲン バイオファーマ カンパニー リミテッド |
神経変性疾患の治療のための組み換えａａｖベクター
|
|
CN119451703A
(zh)
*
|
2022-04-25 |
2025-02-14 |
迈特勒公司 |
髓鞘病症的治疗
|
|
IL316305A
(en)
|
2022-04-25 |
2024-12-01 |
Hadasit Med Res Service |
Methods and preparations for treating vision loss
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
WO2023240220A1
(en)
*
|
2022-06-09 |
2023-12-14 |
The University Of North Carolina At Chapel Hill |
Aav-sgsh vectors for treatment of mucopolysaccharidosis iiia
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
US20260000790A1
(en)
|
2022-07-08 |
2026-01-01 |
Ospedale San Raffaele S.R.L. |
Transgene cassettes
|
|
WO2024015794A2
(en)
*
|
2022-07-12 |
2024-01-18 |
The Research Institute At Nationwide Children's Hospital |
Adeno-associated virus gene therapy products and methods
|
|
AU2023427408A1
(en)
|
2023-02-02 |
2025-09-04 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CN121311595A
(zh)
|
2023-04-17 |
2026-01-09 |
阿斯克生物公司 |
转基因在灵长类动物中可调节的受控表达
|
|
EP4698206A1
(fr)
|
2023-04-21 |
2026-02-25 |
PulseSight Therapeutics |
Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
|
|
GB202306952D0
(en)
*
|
2023-05-11 |
2023-06-28 |
Neurochase Innovations Ltd |
Method
|
|
TW202508610A
(zh)
|
2023-08-23 |
2025-03-01 |
大陸商上海瑞宏迪醫藥有限公司 |
醫藥組成物及其用途
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025160452A1
(en)
|
2024-01-25 |
2025-07-31 |
Genzyme Corporation |
Methods for fus-based delivery of viral particles to the brain
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025160434A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting huntington's disease
|
|
CN120829932A
(zh)
*
|
2024-04-18 |
2025-10-24 |
临港国家实验室 |
治疗眼部疾病的药物组合物及方法
|
|
WO2026150302A1
(en)
|
2025-01-09 |
2026-07-16 |
Novartis Ag |
Novel aav rep/cap encoding constructs
|